Insights

Strategic financing Entera recently secured a substantial $275 million oversubscribed private placement led by BVF Partners, significantly strengthening its runway to advance the EB613 Phase 3 program and pursue the FDA NDA submission.

Clinical momentum The EB613 program has shown positive Phase 2 biomarker and bone Mineral Density outcomes and is preparing for a Phase 3 registrational study, signaling readiness for late-stage engagement and potential payer discussions around a differentiating oral PTH therapy.

Pipeline breadth In addition to EB613, Entera is advancing EB612 for hypoparathyroidism, an oral oxyntomodulin for obesity, and an oral GLP-2 tablet for malabsorption, offering multiple cross-sell opportunities with endocrinology and gastroenterology stakeholders.

Strategic partnerships Chasing collaboration with OPKO Health on the GLP-2 program and ongoing investor visibility from major conferences positions Entera to attract co-development or licensing deals, accelerating clinical timelines and market access potential.

Market readiness Public communications and conference activities, including an upcoming ASBMR presentation and executive visibility, suggest readiness to engage specialty physicians, payers, and patient advocacy groups around oral peptide therapies that could transform standard of care.

Similar companies to Entera Bio Ltd.

Entera Bio Ltd. Tech Stack

Entera Bio Ltd. uses 8 technology products and services including Drupal, Joomla, WordPress, and more. Explore Entera Bio Ltd.'s tech stack below.

Media & News

Entera Bio Ltd.'s Email Address Formats

Entera Bio Ltd. uses at least 3 email formats:
Entera Bio Ltd. Email FormatsExamplePercentage
First@enterabio.comJohn@enterabio.com
71%
First.Last@enterabio.comJohn.Doe@enterabio.com
17%
FirstL@enterabio.comJohnD@enterabio.com
12%

Frequently Asked Questions

What is Entera Bio Ltd.'s stock symbol?

Minus sign iconPlus sign icon
Entera Bio Ltd. is a publicly traded company; the company's stock symbol is ENTX.

What is Entera Bio Ltd.'s official website and social media links?

Minus sign iconPlus sign icon
Entera Bio Ltd.'s official website is enterabio.com and has social profiles on LinkedIn.

How much revenue does Entera Bio Ltd. generate?

Minus sign iconPlus sign icon
As of October 2026, Entera Bio Ltd.'s annual revenue is estimated to be <$1M.

What is Entera Bio Ltd.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Entera Bio Ltd.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Entera Bio Ltd. have currently?

Minus sign iconPlus sign icon
As of October 2026, Entera Bio Ltd. has approximately 24 employees across 3 continents, including Asia, North America and Europe. Key team members include Cfo: D. Y., Coo: H. G. and Chief Medical Officer (evp): R. P. C. Explore Entera Bio Ltd.'s employee directory with LeadIQ.

What industry does Entera Bio Ltd. belong to?

Minus sign iconPlus sign icon
Entera Bio Ltd. operates in the Biotechnology Research industry.

What technology does Entera Bio Ltd. use?

Minus sign iconPlus sign icon
Entera Bio Ltd.'s tech stack includes Drupal, Joomla, WordPress, CookieYes, Shopify, Microsoft 365, Google Cloud and New Relic.

What is Entera Bio Ltd.'s email format?

Minus sign iconPlus sign icon
Entera Bio Ltd.'s email format typically follows the pattern of First@enterabio.com. Find more Entera Bio Ltd. email formats with LeadIQ.

How much funding has Entera Bio Ltd. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Entera Bio Ltd. has raised $40M in funding. The last funding round occurred on Apr 02, 2026.

When was Entera Bio Ltd. founded?

Minus sign iconPlus sign icon
Entera Bio Ltd. was founded in 2010.
Entera Bio Ltd. logo

Entera Bio Ltd.

Biotechnology ResearchIsrael11-50 Employees

Entera Bio Ltd. is a clinical-stage biotechnology company based in Israel focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet could transform care. It relies on a proprietary delivery technology, N-Tab, to enable oral administration of peptide therapeutics and maintains a pipeline of five oral programs expected to enter clinical testing from Phase 1 to Phase 3 by 2025. The most advanced candidate, EB613, targets post-menopausal osteoporosis with low bone mineral density and has shown positive Phase 2 results prompting a planned Phase 3 program. 

Beyond EB613, Entera is advancing EB612 for hypoparathyroidism and other oral peptide therapies, including collaborations with OPKO Health for select programs. The company focuses on offering oral alternatives to injections to address adherence and convenience for patients with obesity, malabsorption syndromes, and related metabolic conditions. A recent development includes positive data presented at ESPEN 2025 for an oral GLP-2 tablet addressing short bowel syndrome, developed in collaboration with OPKO.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ENTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
11-50

Section iconFunding & Financials

  • $40M

    Entera Bio Ltd. has raised a total of $40M of funding over 5 rounds. Their latest funding round was raised on Apr 02, 2026 as a Post IPO Equity.

  • <$1M

    Entera Bio Ltd.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.